Jennifer L Beebe-Dimmer1,2, Ashley L Kapron3, Alison M Fraser3,4, Ken R Smith3,4, Kathleen A Cooney5. 1. Department of Oncology, Wayne State University School of Medicine, Detroit, MI. 2. Barbara Ann Karmanos Cancer Institute, Detroit, MI. 3. University of Utah, Salt Lake City, UT. 4. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. 5. Duke University School of Medicine, Durham, NC.
Abstract
PURPOSE: Recently developed clinical guidelines suggest that men in families with specific cancer syndromes, such as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especially in the setting of aggressive disease. However, although a family history (FH) of the same disease among close relatives is an established risk factor for prostate cancer (PC), a direct comparison of PC risk for men with each syndrome in a single population is needed. METHODS: The Utah Population Database was used to identify 619,630 men, age ≥ 40 years, who were members of a pedigree that included at least 3 consecutive generations. Each man was evaluated for FH of hereditary PC (HPC), HBOC, and Lynch syndrome (LS) and for his own PC status. PC occurrences (N = 36,360) were classified into one or more subtypes: early onset (EO), lethal, and/or clinically significant. Relative risks (RRs) associated with each subtype, adjusted for important covariables, were calculated in STATA using a modified Poisson regression with robust error variances to obtain corresponding RR CIs for each FH definition. RESULTS: An FH of HPC conveyed the greatest relative risk for all PC subtypes combined (RR, 2.30; 95% CI, 2.22 to 2.40), followed by HBOC and LS (both with 1 < RR < 2 and statistically significant). The strongest risks associated with FH were observed for EO disease in all pedigree types, consistent with the contribution of genetic factors to disease occurrence. CONCLUSION: In this large, population-based, family database, the risk of PC varied by cancer FH and was most strongly associated with EO disease. These results are critically valuable in understanding and targeting high-risk populations that would benefit from genetic screening and enhanced surveillance.
PURPOSE: Recently developed clinical guidelines suggest that men in families with specific cancer syndromes, such as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especially in the setting of aggressive disease. However, although a family history (FH) of the same disease among close relatives is an established risk factor for prostate cancer (PC), a direct comparison of PC risk for men with each syndrome in a single population is needed. METHODS: The Utah Population Database was used to identify 619,630 men, age ≥ 40 years, who were members of a pedigree that included at least 3 consecutive generations. Each man was evaluated for FH of hereditary PC (HPC), HBOC, and Lynch syndrome (LS) and for his own PC status. PC occurrences (N = 36,360) were classified into one or more subtypes: early onset (EO), lethal, and/or clinically significant. Relative risks (RRs) associated with each subtype, adjusted for important covariables, were calculated in STATA using a modified Poisson regression with robust error variances to obtain corresponding RR CIs for each FH definition. RESULTS: An FH of HPC conveyed the greatest relative risk for all PC subtypes combined (RR, 2.30; 95% CI, 2.22 to 2.40), followed by HBOC and LS (both with 1 < RR < 2 and statistically significant). The strongest risks associated with FH were observed for EO disease in all pedigree types, consistent with the contribution of genetic factors to disease occurrence. CONCLUSION: In this large, population-based, family database, the risk of PC varied by cancer FH and was most strongly associated with EO disease. These results are critically valuable in understanding and targeting high-risk populations that would benefit from genetic screening and enhanced surveillance.
Authors: Brian T Helfand; Haitao Chen; Richard J Fantus; Carly A Conran; Charles B Brendler; Siquan Lilly Zheng; Patrick C Walsh; William B Isaacs; Jianfeng Xu Journal: Prostate Date: 2018-06-19 Impact factor: 4.104
Authors: Peter R Carroll; J Kellogg Parsons; Gerald Andriole; Robert R Bahnson; Daniel A Barocas; Erik P Castle; William J Catalona; Douglas M Dahl; John W Davis; Jonathan I Epstein; Ruth B Etzioni; Thomas Farrington; George P Hemstreet; Mark H Kawachi; Paul H Lange; Kevin R Loughlin; William Lowrance; Paul Maroni; James Mohler; Todd M Morgan; Robert B Nadler; Michael Poch; Chuck Scales; Terrence M Shaneyfelt; Marc C Smaldone; Geoffrey Sonn; Preston Sprenke; Andrew J Vickers; Robert Wake; Dorothy A Shead; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2015-12 Impact factor: 11.908
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Jennifer L Beebe-Dimmer; William B Isaacs; Kimberly A Zuhlke; Cecilia Yee; Patrick C Walsh; Sarah D Isaacs; Anna M Johnson; Charles E Ewing; Elizabeth B Humphreys; Wasim H Chowdhury; James E Montie; Kathleen A Cooney Journal: BJU Int Date: 2014-03-05 Impact factor: 5.588
Authors: Frederick Albright; Robert A Stephenson; Neeraj Agarwal; Craig C Teerlink; William T Lowrance; James M Farnham; Lisa A Cannon Albright Journal: Prostate Date: 2014-11-18 Impact factor: 4.104
Authors: Robert Szulkin; Robert Karlsson; Thomas Whitington; Markus Aly; Henrik Gronberg; Rosalind A Eeles; Douglas F Easton; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch; Kenneth Muir; Graham G Giles; Melissa C Southey; Liesel M FitzGerald; Brian E Henderson; Fredrick R Schumacher; Christopher A Haiman; Csilla Sipeky; Teuvo L J Tammela; Børge G Nordestgaard; Timothy J Key; Ruth C Travis; David E Neal; Jenny L Donovan; Freddie C Hamdy; Paul D P Pharoah; Nora Pashayan; Kay-Tee Khaw; Janet L Stanford; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Jan Lubiński; Wojciech Kluźniak; Lisa Cannon-Albright; Hermann Brenner; Volker Herrmann; Bernd Holleczek; Jong Y Park; Thomas A Sellers; Hui-Yi Lim; Chavdar Slavov; Radka P Kaneva; Vanio I Mitev; Amanda Spurdle; Manuel R Teixeira; Paula Paulo; Sofia Maia; Hardev Pandha; Agnieszka Michael; Andrzej Kierzek; Jyotsna Batra; Judith A Clements; Demetrius Albanes; Gerald L Andriole; Sonja I Berndt; Stephen Chanock; Susan M Gapstur; Edward L Giovannucci; David J Hunter; Peter Kraft; Loic Le Marchand; Jing Ma; Alison M Mondul; Kathryn L Penney; Meir J Stampfer; Victoria L Stevens; Stephanie J Weinstein; Antonia Trichopoulou; Bas H Bueno-de-Mesquita; Anne Tjønneland; David G Cox; Lovise Maehle; Johanna Schleutker; Sara Lindström; Fredrik Wiklund Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-08-25 Impact factor: 4.254
Authors: Matthew B Clements; Emily A Vertosick; Lourdes Guerrios-Rivera; Amanda M De Hoedt; Javier Hernandez; Michael A Liss; Robin J Leach; Stephen J Freedland; Alexander Haese; Francesco Montorsi; Stephen A Boorjian; Cedric Poyet; Donna P Ankerst; Andrew J Vickers Journal: Eur Urol Date: 2021-12-31 Impact factor: 24.267
Authors: Luigi A M J G van Riel; Auke Jager; Dennie Meijer; Arnoud W Postema; Ruth S Smit; André N Vis; Theo M de Reijke; Harrie P Beerlage; Jorg R Oddens Journal: Ther Adv Urol Date: 2022-03-26
Authors: Ana Paula Alarcón-Zendejas; Anna Scavuzzo; Miguel A Jiménez-Ríos; Rosa M Álvarez-Gómez; Rogelio Montiel-Manríquez; Clementina Castro-Hernández; Miguel A Jiménez-Dávila; Delia Pérez-Montiel; Rodrigo González-Barrios; Francisco Jiménez-Trejo; Cristian Arriaga-Canon; Luis A Herrera Journal: Prostate Cancer Prostatic Dis Date: 2022-04-14 Impact factor: 5.455